Comparison · Lipolysis & GH-axis
AOD-9604 vs Tesamorelin
Two compounds often grouped together because both appear in body-composition research — but they work on completely different pathways. Here's how they compare.
Reading this research reference
The information below concerns the research subject, not proof of the identity or performance of a supplied material. Check the original sources and your laboratory’s requirements; product documentation must be assessed separately for the exact batch.
At a glance
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Class | hGH 176-191 fragment | GHRH analogue |
| Mechanism | Lipolysis / fat-oxidation pathways | Endogenous GH + IGF-1 release |
| Affects IGF-1? | No | Yes |
| Research strength | Mostly preclinical | Extensive clinical literature |
| Half-life | Short (minutes) | ~26 minutes (sustained GH pulse) |
Mechanism
AOD-9604 is a synthetic fragment corresponding to the C-terminal 176–191 of human GH; research suggests it modulates lipolysis without binding the GH receptor itself. Tesamorelin is a stabilised GHRH analogue that triggers endogenous GH release from the pituitary.
Body-composition research
Tesamorelin is best characterised in clinical research on visceral adipose tissue reduction in HIV-associated lipodystrophy. AOD-9604's body-composition data is largely preclinical and animal-based.
Side-effect signal
Because AOD-9604 does not raise IGF-1, its side-effect profile in research is distinct from GH-axis compounds. Tesamorelin can show GH-related effects (joint stiffness, glucose shifts) consistent with its mechanism.
Which fits which study
Investigators studying lipolysis pathways without confounding GH/IGF-1 movement favour AOD-9604. Investigators studying endogenous GH axis manipulation favour Tesamorelin.
Frequently asked questions
Are AOD-9604 and Tesamorelin both GH-related?+
Yes, but in opposite directions. AOD-9604 is a fragment of human growth hormone that acts on lipolysis pathways without raising IGF-1. Tesamorelin is a GHRH analogue that drives endogenous GH and IGF-1 release.
Which is better-studied for visceral fat?+
Tesamorelin has the more extensive clinical research base for visceral adipose reduction. AOD-9604's data is largely preclinical.
Do they affect IGF-1 differently?+
Tesamorelin elevates IGF-1 via GH release; AOD-9604 does not.
Tesamorelin vs AOD-9604 on Bio Mech
Product details, batch documentation and support for the compounds discussed above. Research use only.
Continue your research
Order in 3 steps · tracked delivery
Order research peptides for your laboratory
Batch documentation is provided on request — no laboratory reports have yet been verified for publication against Bio Mech stock. Dispatch is tracked on every order; allow 5–18 business days once tracking is active. Supplied for in-vitro research use only.
- 1
Choose your compound
Browse the catalog or search for a specific reference standard.
- 2
Checkout in 2 minutes
Bank transfer or card — the full price is shown before you pay.
- 3
Tracked dispatch
Tracking on every order; 5–18 business days once tracking is active.
Most ordered this month
BPC-157
From €269.00
Ipamorelin
From €249.00
Bacteriostatic Water
From €149.00
- Research use only — not for human consumption
- Tracked delivery to the USA, UK, Europe and the Middle East
- Batch documentation available on request
Research materials · Order information
Research only
Not for human consumption
Documentation
Ask about the specific batch
Tracked parcels
5–18 business days
Tracked Delivery
5–18 business days
Pay with Wise, Revolut, Monzo, bunq or bank transfer
- Card via Wise
- Card via Revolut
- Bank Transfer